Erythronate
Introduction
Erythronate is a four-carbon sugar acid, a derivative of erythrose, involved in various metabolic pathways. While not directly a hematological phenotype, its levels or metabolism can reflect broader physiological states that influence red blood cell health and function. Genetic studies have extensively investigated the molecular underpinnings of numerous hematological phenotypes, including hemoglobin levels, mean corpuscular hemoglobin, red blood cell count, and hematocrit. [1] Understanding the genetic factors that influence these fundamental traits is essential for clarifying the biological basis of blood-related disorders and their impact on overall cardiovascular health. [2]
Biological Basis
The biological basis of hematological traits is intricate, involving genes that regulate the production, maturation, and function of red blood cells. Genome-wide association studies (GWAS) have identified specific genetic variants associated with key hematological phenotypes. [1] For instance, SNPs within the beta hemoglobin gene cluster on chromosome 11, including _HBB_, _HBD_, _HBG1_, _HBG2_, and _HBE1_, have shown significant associations with hematocrit. [1] Other candidate genes that have been investigated for their roles in hematological traits include _EPOR_, _EPO_, _KLF1_, _HBA1_, _HBA2_, and _HBM_. [1] Additionally, variants in _HK1_ have been associated with glycated hemoglobin levels in non-diabetic populations [3] and _BCL11A_ is linked to persistent fetal hemoglobin, a factor in the amelioration of conditions like beta-thalassemia. [4] These genetic insights underscore the complex molecular mechanisms that govern red blood cell characteristics and metabolism.
Clinical Relevance
The clinical relevance of hematological phenotypes, and by extension any related metabolic biomarkers, is substantial. Abnormalities in red blood cell parameters are critical for the diagnosis and management of a wide spectrum of conditions, such as various forms of anemia, polycythemia, and hemoglobinopathies like beta-thalassemia. [4] For example, specific SNPs have been linked to mean corpuscular hemoglobin concentration, which is a key indicator of red blood cell size and hemoglobin content. [1] Genetic variants influencing hemoglobin levels, such as those associated with the _HBB_ gene cluster and _HK1_, can directly affect the body's oxygen transport capacity and contribute to the risk or severity of cardiovascular diseases. [3] Furthermore, the understanding of genetic associations with persistent fetal hemoglobin, particularly with _BCL11A_, offers promising therapeutic avenues for individuals with beta-thalassemia. [4]
Social Importance
The social importance of understanding hematological health is profound, as these traits impact a significant portion of the global population. Conditions stemming from dysregulated red blood cell function can lead to chronic fatigue, diminished quality of life, and considerable healthcare expenditures. Genetic research into these phenotypes provides crucial insights for the advancement of personalized medicine, enabling earlier identification of at-risk individuals, the development of more precise diagnostic tools, and the creation of targeted therapeutic strategies. By elucidating the genetic architecture of hematological traits, researchers contribute to public health initiatives focused on preventing and managing widespread blood disorders, thereby enhancing overall societal well-being.
Methodological and Statistical Constraints
Genetic association studies, including genome-wide association studies (GWAS), are inherently limited by their study design and statistical power. Many studies face challenges with sample size, which can restrict the ability to detect genetic effects of modest size, increasing the risk of false negative findings. [5] For instance, while some studies may have sufficient power to detect variants explaining a substantial portion of phenotypic variation (e.g., 4% or more), they may lack the capacity to identify associations with smaller effect sizes, which are common in complex traits. [6] Conversely, the extensive multiple testing inherent in GWAS can lead to false positive results, even when strong statistical evidence is present. [5] This is further complicated by the observation that some associations, such as those involving rs2305198 and rs7072268 with glycated hemoglobin, may only reach statistical significance when analyzed in a multiple regression model rather than individually, highlighting the sensitivity of findings to the chosen statistical approach. [3]
Replication of initial findings across independent cohorts is crucial but often presents its own set of challenges. Discrepancies can arise because different studies may use varying marker sets with limited overlap, necessitating imputation of missing genotypes, which introduces a small but inherent error rate. [7] Furthermore, non-replication at the single nucleotide polymorphism (SNP) level can occur if different studies identify distinct SNPs within the same gene region that are in strong linkage disequilibrium with an unknown causal variant but not with each other, or if multiple causal variants exist within a gene. [8] Practical limitations, such as the inability to design robust probes for the strongest associated SNP, may also force researchers to follow up proxy SNPs, potentially impacting the precision of replication efforts. [4]
Population and Phenotype Heterogeneity
The generalizability of findings from genetic studies can be constrained by the characteristics of the study populations and the methods used for phenotype assessment. Studies relying on specific cohorts, such as twins or volunteers, may not fully reflect the genetic architecture or prevalence of traits in the broader general population. [9] While some research indicates no significant phenotypic differences between twins and non-twins for certain markers, the volunteer nature of participation can introduce selection bias, the impact of which on genetic associations requires careful consideration. [9] Ancestry and population stratification also pose significant challenges, as genetic associations can be confounded by underlying population structure. Although methods like genomic control and principal component analysis are often employed to adjust for such stratification, their effectiveness relies on accurate modeling and sufficient genetic diversity within the cohorts. [10]
Phenotype measurement itself is a critical area of limitation. The accurate and consistent assessment of traits is paramount, as variations in collection protocols can introduce substantial noise. For example, serum markers for iron status are known to be influenced by factors such as the time of day blood is collected and menopausal status, necessitating careful standardization or adjustment in analyses. [9] The estimation of genetic variance explained by SNPs often relies on the assumption that phenotypic variance and heritability estimates are accurate, underscoring the importance of robust phenotyping. [9] While some studies average trait measurements across multiple examinations to mitigate variability, this approach also acknowledges the inherent fluctuations and potential for measurement error in complex phenotypes. [6]
Unexplored Biological and Environmental Contexts
A significant limitation in understanding the complete genetic landscape of a phenotype is the often-unexplored role of environmental factors and gene-environment interactions. Genetic variants do not operate in isolation; their influence on phenotypes can be highly context-specific and modulated by environmental exposures. [6] For instance, associations between specific genes like ACE and AGTR2 with left ventricular mass have been shown to vary with dietary salt intake, yet many studies, due to design or resource constraints, do not undertake comprehensive investigations into these complex interactions. [6] This oversight means that a substantial portion of the genetic contribution to a trait, often referred to as "missing heritability," may remain unexplained because the full interplay between genes and environment is not captured.
Furthermore, current genome-wide association studies, despite their broad scope, typically use only a subset of all available genetic variants, such as those in HapMap, potentially missing novel genes or comprehensive coverage of candidate genes due to incomplete representation of genetic variation. [1] The inability to conduct sex-specific analyses to avoid increasing the multiple testing burden can also mask associations that are present only in males or females, leading to an incomplete understanding of genetic influences across sexes. [1] These limitations highlight the ongoing need for studies with more comprehensive genetic coverage, detailed environmental data, and sophisticated analytical approaches to fully elucidate the genetic and environmental determinants of complex human traits.
Variants
Genetic variations play a crucial role in influencing a wide array of biological processes, including metabolic pathways and cellular functions that can indirectly impact erythronate levels. Variants within genes involved in carbohydrate metabolism, cellular signaling, and ion transport can alter enzyme activity, protein function, or gene expression, leading to downstream effects on red blood cell health and overall metabolic homeostasis. Genome-wide association studies (GWAS) frequently identify such single nucleotide polymorphisms (SNPs) that are associated with various quantitative traits and disease risks. [11] Understanding these genetic underpinnings helps elucidate the complex interplay between genotype and phenotype.
Variants in genes like _TKT_ and _FGF21_ are central to metabolic regulation. The _TKT_ gene, encoding transketolase, is an enzyme vital to the pentose phosphate pathway, which generates NADPH for antioxidant defense and precursors for nucleotide synthesis. Specific variants such as rs4687717, rs4687718, and rs73840299 in _TKT_ could potentially modify enzyme efficiency, thereby impacting the cell's ability to manage oxidative stress and synthesize essential biomolecules, which is particularly relevant for the high metabolic demands of red blood cells and could influence erythronate-related pathways. Similarly, _FGF21_ is a hormone critical for glucose and lipid metabolism, regulating energy balance and insulin sensitivity. The rs1698113 variant in _FGF21_ may alter its expression or activity, potentially affecting systemic metabolic control and thus influencing the production or clearance of erythronate, a byproduct of carbohydrate metabolism. [11] Additionally, _CACNA1D_ encodes a subunit of an L-type calcium channel, essential for cellular signaling and hormone secretion. The rs681751 variant within _CACNA1D_ could modulate calcium influx, thereby impacting cellular excitability and diverse metabolic processes that are broadly linked to erythronate metabolism.
Other variants affect genes involved in cell regulation and proteostasis. _PTPRA_ encodes a receptor-type protein tyrosine phosphatase, an enzyme that dephosphorylates tyrosine residues and is involved in crucial signaling pathways regulating cell growth and differentiation. The rs147527090 variant in _PTPRA_ could influence its enzymatic activity, potentially altering cellular signaling cascades vital for red blood cell development and overall metabolic function. The region encompassing _GMNC_ (Geminin Coiled-Coil Domain Containing) and _OSTN_ (Osteocrin), with the variant rs9842055, suggests potential roles in cell cycle regulation and bone metabolism, respectively. Changes here could affect cell proliferation or broader metabolic health. Furthermore, _PACRG_ (Parkin Co-Regulated Gene), with its variant rs16888819, is implicated in protein quality control and cellular stress responses, processes fundamental to maintaining the integrity and function of all cells, including those involved in erythronate metabolism. [12]
Finally, the region including _RPL34P18_ (Ribosomal Protein L34 Pseudogene 18) and _CDH17_ (Cadherin 17), featuring the variant rs876324, points to roles in protein synthesis and cell adhesion. While _RPL34P18_ is a pseudogene, its proximity to _CDH17_, a gene involved in cell-cell adhesion within epithelial tissues, suggests that rs876324 could influence the expression or function of _CDH17_. Disruptions in cell adhesion or protein production pathways can have systemic metabolic consequences, indirectly affecting the cellular environment and metabolic byproducts like erythronate. [1] These genetic variations collectively highlight the intricate genetic architecture underpinning metabolic traits and their potential relevance to erythronate.
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs4687717 rs4687718 rs73840299 |
TKT | erythritol measurement erythronate measurement serum metabolite level phosphate-to-erythronate ratio |
| rs681751 | CACNA1D | erythronate measurement |
| rs9842055 | GMNC - OSTN | protein measurement erythronate measurement cerebrospinal fluid composition attribute, C-glycosyltryptophan measurement brain connectivity attribute amygdala volume |
| rs1698113 | FGF21 | erythronate measurement level of elastin in blood fatty acid amount triglyceride measurement |
| rs147527090 | PTPRA | erythronate measurement |
| rs16888819 | PACRG | ocular sarcoidosis erythronate measurement |
| rs876324 | RPL34P18 - CDH17 | erythronate measurement |
Red Blood Cell Metabolism and Energy Homeostasis
Red blood cells primarily rely on glycolysis for their energy needs, as they lack mitochondria and thus cannot perform oxidative phosphorylation. A critical enzyme in this metabolic pathway is Hexokinase 1 (HK1), which catalyzes the first committed step of glycolysis, phosphorylating glucose to glucose-6-phosphate. [3] This initial step is vital for trapping glucose within the cell and committing it to energy production, maintaining the cell's integrity and functions, such as ion transport and maintaining membrane shape.
Dysfunctions or abnormalities in erythrocyte enzymes involved in glycolysis can lead to significant disruptions in cellular energy homeostasis. [13] Such enzymatic defects can impair ATP production, making red blood cells vulnerable to oxidative stress and reducing their lifespan. These metabolic aberrations can manifest as various hematological phenotypes, impacting overall red blood cell count (RBCC), hemoglobin content (Hgb), and mean corpuscular hemoglobin (MCH). [1]
Hemoglobin Synthesis and Oxygen Transport
Hemoglobin is the primary protein responsible for oxygen transport in red blood cells, composed of multiple globin chains encoded by distinct gene clusters. Adult hemoglobin typically consists of alpha-globin (HBA1, HBA2) and beta-globin (HBB) chains, while fetal hemoglobin contains gamma-globin (HBG1, HBG2) chains, which are later replaced by adult forms . [1], [14] The proper synthesis and assembly of these globin chains are crucial for the hemoglobin molecule's oxygen-binding capacity and the overall health of red blood cells. Heme binding protein 2 (HEBP2) also plays a role in heme metabolism, which is essential for hemoglobin formation. [1]
The production of fetal hemoglobin is tightly regulated, with the gene BCL11A (B-cell lymphoma/leukemia 11A) identified as a key genetic modulator influencing F cell (fetal hemoglobin-containing red blood cell) production. [14] Variants in BCL11A can lead to persistent fetal hemoglobin, a phenomenon that has significant pathophysiological implications, particularly in ameliorating the severe phenotype of beta-thalassemia by compensating for defective adult hemoglobin synthesis. [4] This genetic mechanism highlights a critical compensatory response in certain hematological disorders.
Erythrocyte Structure and Membrane Integrity
The structural integrity and unique biconcave shape of red blood cells are essential for their function in navigating narrow capillaries and efficiently exchanging gases. This shape and flexibility are maintained by a complex network of membrane-associated proteins, including the erythrocyte membrane protein band 4.1-like 2 (EPB41L2). [1] EPB41L2 contributes to the mechanical stability of the red blood cell membrane, linking the lipid bilayer to the underlying spectrin-actin cytoskeleton.
Genetic variations or defects in genes encoding these structural proteins, such as EPB41L2, can compromise the deformability and stability of red blood cells, leading to their premature destruction and various hematological disorders. [1] Maintaining a healthy red blood cell membrane is thus critical for their survival in circulation and for ensuring effective oxygen delivery throughout the body.
Genetic and Regulatory Mechanisms of Erythroid Development
Erythroid development, the process of red blood cell formation, is a highly orchestrated genetic program controlled by a network of transcription factors and regulatory elements. Kruppel-like factor 1 (KLF1) is a crucial transcription factor known to regulate the expression of numerous genes involved in erythroid differentiation, including those responsible for hemoglobin synthesis and red blood cell structural components. [1] Its precise regulation is vital for the maturation of erythroid progenitor cells into functional red blood cells.
Beyond KLF1, other genetic factors like BCL11A also play a significant role in modulating gene expression during erythropoiesis, particularly in the developmental switch from fetal to adult hemoglobin production. [14] Understanding these intricate genetic and regulatory networks is fundamental to comprehending the causes of various anemias and other hematological conditions, as well as for developing therapeutic strategies.
Metabolic Flux and Nutrient Transport
Cellular energy metabolism and nutrient transport are foundational processes, intricately regulated to maintain homeostasis. In red blood cells, glycolysis, a central metabolic pathway, is essential for generating ATP, with enzyme abnormalities in this pathway leading to compromised erythrocyte function and survival. [13] Key glycolytic enzymes, such as Hexokinase 1 (HK1), are involved in the initial phosphorylation of glucose, and variations in genes like HK1 have been associated with glycated hemoglobin levels, indicating its broader significance in metabolic regulation beyond just red blood cells. [15] Furthermore, the mevalonate pathway, crucial for cholesterol biosynthesis, and related isoprenoid metabolism, are tightly controlled through mechanisms involving transcription factors like SREBP-2, linking lipid metabolism to overall cellular function. [16]
Beyond energy and lipid metabolism, the transport of specific nutrients and waste products is vital. The SLC2A9 gene, encoding the GLUT9 protein, functions as a critical urate transporter, influencing serum uric acid levels and playing a role in conditions like gout. [17] This transporter is involved in the active biological transport of substances, including fructose, with alternative splicing of GLUT9 affecting its trafficking and substrate selectivity, highlighting a complex regulatory layer for nutrient and waste management within the body. [18] The dysregulation of urate metabolism, often mediated by transporters like SLC2A9, can contribute to metabolic syndrome and renal disease. [19]
Intracellular Signaling and Regulatory Networks
Intracellular signaling cascades orchestrate cellular responses to various stimuli, integrating external cues into specific cellular actions. The mitogen-activated protein kinase (MAPK) pathway is a prominent example, with its activation being critical in processes such as muscle adaptation to exercise and its regulation involving protein families like human tribbles. [20] Another crucial signaling axis involves cyclic AMP (cAMP) and cyclic GMP (cGMP), where phosphodiesterase 5 (PDE5) regulates cGMP levels, and its expression can be modulated by factors like Angiotensin II, thereby influencing vascular smooth muscle cell function and antagonizing cGMP signaling. [21] The CFTR chloride channel, whose activity is cAMP-dependent, further exemplifies the importance of these second messenger systems in regulating ion transport and mechanical properties of cells. [21]
Receptor activation often initiates these cascades, leading to intricate intracellular communication. For instance, the neuronal chemorepellent Slit2 inhibits vascular smooth muscle cell migration by suppressing the activation of small GTPase Rac1, illustrating a signaling pathway that controls cell motility and tissue organization. [22] Calcium signaling, mediated by proteins like the cardiac ryanodine receptor (hRyR2), is fundamental for muscle contraction and other cellular processes, with mutations in hRyR2 being implicated in catecholaminergic polymorphic ventricular tachycardia, demonstrating the critical role of precise signaling in maintaining physiological function. [23] The phosphorylation of proteins like Heat Shock Protein-90 by TSH further illustrates how receptor-mediated signaling can lead to post-translational modifications that alter protein function. [24]
Genomic and Post-Translational Control Mechanisms
Gene regulation and protein modification are fundamental mechanisms that dictate cellular identity and function. Transcriptional regulation, often involving specific transcription factors, finely tunes gene expression in response to physiological needs; for example, SREBP-2 regulates genes in the mevalonate pathway, linking lipid metabolism to gene activity. [25] Beyond transcription, alternative splicing is a powerful post-transcriptional mechanism, where different mRNA isoforms can be produced from a single gene, leading to protein variants with distinct functions or localizations, as seen with GLUT9 where alternative splicing alters its trafficking. [18] This precise control also extends to genes like HMGCR, where common single nucleotide polymorphisms (SNPs) can affect alternative splicing of specific exons, impacting protein production and function. [26]
Protein modification further refines protein activity and stability after translation. Post-translational modifications, such as phosphorylation, are critical for activating or deactivating proteins within signaling cascades, exemplified by the phosphorylation of Heat Shock Protein-90 by TSH. [24] Protein trafficking and localization are also tightly controlled, influencing where a protein exerts its function; for instance, the identification of Erlin-1 and Erlin-2 as prohibitin family members defining lipid-raft-like domains of the ER suggests their role in organizing protein complexes and membrane dynamics. [27] These multi-layered regulatory mechanisms ensure that proteins are produced correctly, modified appropriately, and delivered to their proper cellular compartments to maintain physiological balance.
Inter-Pathway Communication and Disease Pathogenesis
Biological systems operate through highly interconnected networks, where pathways frequently crosstalk, and dysregulation in one can have cascading effects on others, leading to complex disease phenotypes. The metabolic syndrome, for example, is a cluster of conditions where dysregulated uric acid metabolism, influenced by transporters like SLC2A9, is intertwined with renal disease, demonstrating how metabolic pathways are integrated at a systems level. [19] Similarly, the Angiotensin II signaling pathway not only impacts vascular smooth muscle cells but also antagonizes cGMP signaling by increasing PDE5A expression, illustrating a direct molecular crosstalk between hormonal regulation and cyclic nucleotide signaling. [21] These network interactions highlight how compensatory mechanisms might arise or fail, contributing to the progression of disease.
Pathway dysregulation is a common underlying factor in many diseases, often presenting as complex traits influenced by multiple genetic and environmental factors. For instance, genetic variants in genes such as CDKAL1, IGF2BP2, CDKN2A/B, HHEX, SLC30A8, and KCNJ11 are associated with susceptibility to type 2 diabetes, indicating the polygenic nature of metabolic disorders. [28] In cardiovascular disease, dyslipidemia, characterized by abnormal lipid concentrations, is influenced by common variants at multiple loci, including those impacting the mevalonate pathway, linking lipid metabolism to cardiac health. [7] Understanding these integrated pathways and their dysregulation is crucial for identifying therapeutic targets, such as the urate transporter SLC2A9 for gout, or enzymes in glycolysis for erythrocyte disorders. [17]
Clinical Relevance of Erythronate
Erythronate, encompassing various hematological parameters such as hemoglobin, hematocrit, red blood cell count, and glycated hemoglobin, plays a crucial role in assessing patient health and disease risk. Insights from genome-wide association studies (GWAS) and clinical investigations highlight its utility in prognosis, diagnosis, and guiding personalized medical strategies.
Prognostic and Diagnostic Utility in Cardiovascular and Metabolic Disease
Erythronate-related biomarkers offer significant prognostic value, aiding in the prediction of various disease outcomes. Hemoglobin levels, for instance, have been identified as predictors of cerebral infarction risk. [29] Glycated hemoglobin (HbA1c) is a well-established and indispensable biomarker for the diagnosis of diabetes and the monitoring of its progression, providing a reliable measure of long-term glycemic control. [30] Beyond diabetes, elevated HbA1c levels have been independently associated with an increased risk of cardiovascular disease and mortality in both diabetic and non-diabetic populations, serving as a significant predictor of stroke and coronary events. [31] While HbA1c consistently predicts diabetes, its direct predictive value for cardiovascular disease in non-diabetic women has been a subject of specific inquiry. [32]
Genetic Determinants and Associated Conditions
Genome-wide association studies (GWAS) have uncovered specific genetic variants that influence erythronate-related phenotypes, providing valuable insights into their underlying biological regulation and potential predispositions. For example, single nucleotide polymorphisms (SNPs) located within or near genes such as HBB, HBD, HBG1, HBG2, and HBE1 exhibit strong associations with hematocrit levels. [1] Similarly, variants within EPB41L2 (erythrocyte membrane protein band 4.1-like 2) have been significantly linked to various hematological phenotypes, including mean corpuscular hemoglobin concentration. [1] These genetic findings underscore the complex interplay of genetic factors in determining erythron characteristics and their variability among individuals.
Beyond general hematological parameters, specific genetic associations highlight connections to distinct clinical conditions and complications. For instance, variants in BCL11A are notably associated with persistent fetal hemoglobin production, a factor known to ameliorate the severity of beta-thalassemia phenotypes [4] demonstrating a direct genetic link to a specific erythroid disorder and potential therapeutic targets. While not a direct comorbidity, observations from cohorts like the BRIGHT study indicate that individuals with hypertension may also present with other systemic alterations, such as slightly reduced creatinine clearance and elevated triglyceride levels [2] suggesting potential broader physiological contexts that could indirectly influence or be influenced by erythronate parameters.
Risk Stratification and Personalized Patient Care
The established prognostic capabilities of erythronate-related biomarkers, particularly hemoglobin and glycated hemoglobin, are instrumental in stratifying individuals according to their risk for various adverse health outcomes. Early identification of individuals with aberrant hemoglobin or elevated HbA1c levels allows clinicians to implement targeted prevention strategies and monitor disease progression more effectively, potentially mitigating the incidence of cardiovascular events, stroke, and diabetes-related complications. [29] This proactive approach facilitates more effective patient management, moving beyond reactive treatment.
Genetic insights into erythronate regulation offer promising avenues for personalized medicine, tailoring interventions based on an individual's unique genetic profile. For instance, understanding genetic predispositions, such as those impacting fetal hemoglobin persistence, can inform individualized therapeutic strategies for conditions like beta-thalassemia. [4] Furthermore, ongoing monitoring of key erythronate parameters, such as hemoglobin, is crucial in managing patients with comorbidities like renal insufficiency, which is a known predictor of cardiovascular outcomes and mortality [33] enabling adjustments to treatment and care plans to optimize patient well-being and long-term health.
References
[1] Yang, Q. "Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study." BMC Med Genet, 2007.
[2] Wallace, C. "Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia." American Journal of Human Genetics, vol. 82, no. 1, 2008, pp. 138-49.
[3] Pare, G. "Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women." PLoS Genet, 2008.
[4] Uda, M. "Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia." Proc Natl Acad Sci U S A, 2008.
[5] Benjamin, E. J. "Genome-wide association with select biomarker traits in the Framingham Heart Study." BMC Med Genet, 2007.
[6] Vasan, R. S. "Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study." BMC Med Genet, 2007.
[7] Willer, C. J. "Newly identified loci that influence lipid concentrations and risk of coronary artery disease." Nat Genet, 2008.
[8] Sabatti, C. "Genome-wide association analysis of metabolic traits in a birth cohort from a founder population." Nat Genet, 2009.
[9] Benyamin, B. "Variants in TF and HFE explain approximately 40% of genetic variation in serum-transferrin levels." Am J Hum Genet, 2009.
[10] Dehghan, A. "Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study." Lancet, 2008.
[11] Hwang, Shih-Jen, et al. "A genome-wide association for kidney function and endocrine-related traits in the NHLBI's Framingham Heart Study." BMC Medical Genetics, vol. 8, no. S1, 2007, p. S10.
[12] Melzer, David, et al. "A genome-wide association study identifies protein quantitative trait loci (pQTLs)." PLoS Genetics, vol. 4, no. 5, 2008, p. e1000072.
[13] van Wijk, R., and van Solinge, W. W. "The energy-less red blood cell is lost: erythrocyte enzyme abnormalities of glycolysis." Blood, vol. 106, 2005, pp. 4034–4042.
[14] Menzel, S. "A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15." Nat Genet, 2007.
[15] Pare, G. "Novel association of HK1 with glycated hemoglobin in a non-diabetic population: a genome-wide evaluation of 14,618 participants in the Women's Genome Health Study." PLoS Genet, 2009.
[16] Goldstein, J. L., and Brown, M. S. "Regulation of the mevalonate pathway." Nature, vol. 343, 1990, pp. 425–430.
[17] Vitart, V., et al. "SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout." Nat Genet, vol. 40, no. 4, 2008, pp. 437-42.
[18] Augustin, R., et al. "Identification and characterization of human glucose transporter-like protein-9 (GLUT9): alternative splicing alters trafficking." J Biol Chem, vol. 279, no. 16, 2004, pp. 16229–36.
[19] Cirillo, P., et al. "Uric Acid, the metabolic syndrome, and renal disease." J Am Soc Nephrol, vol. 17, no. 12 Suppl 3, 2006, pp. S165–S168.
[20] Vasan, R. S., et al. "Activated protein kinase (MAPK) pathway activation: effects of age and acute exercise on human skeletal muscle." J Physiol, vol. 547, 2003, pp. 977-987.
[21] Vasan, R. S., et al. "Angiotensin II increases phosphodiesterase 5A expression in vascular smooth muscle cells: a mechanism by which angiotensin II antagonizes cGMP signaling." J Mol Cell Cardiol, vol. 38, 2005, pp. 175-184.
[22] Liu, D., et al. "Neuronal chemorepellent Slit2 inhibits vascular smooth muscle cell migration by suppressing small GTPase Rac1 activation." Circ Res, vol. 98, 2006, pp. 480–489.
[23] Priori, S. G., et al. "Mutations in the Cardiac Ryanodine Receptor Gene (hRyR2) Underlie Catecholaminergic Polyventricular Tachycardia." Circulation, vol. 103, 2003, pp. 196-200.
[24] Hwang, S. J., et al. "Phosphorylation of Heat Shock Protein-90 by TSH in FRTL-5 Thyroid Cells." Thyroid, vol. 16, 2006, pp. 737-742.
[25] Murphy, C., et al. "Regulation by SREBP-2 defines a potential link between isoprenoid and adenosylcobalamin metabolism." Biochem Biophys Res Commun, vol. 355, 2007, pp. 359–364.
[26] Burkhardt, R., et al. "Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13." Arterioscler Thromb Vasc Biol, 2008.
[27] Browman, D. T., et al. "Erlin-1 and erlin-2 are novel members of the prohibitin family of proteins that define lipid-raft-like domains of the ER." J. Cell Sci., vol. 119, 2006, pp. 3149–3160.
[28] Omori, S., et al. "Association of CDKAL1, IGF2BP2, CDKN2A/B, HHEX, SLC30A8, and KCNJ11 with susceptibility to type 2 diabetes in a Japanese population." Diabetes, vol. 57, 2008, pp. 791–795.
[29] Kannel, William B., et al. "Hemoglobin and the risk of cerebral infarction: the Framingham Study." Stroke, vol. 3, 1972, pp. 409-420.
[30] The Diabetes Control and Complications Trial Research Group. "The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus." New England Journal of Medicine, vol. 329, 1993, pp. 977–986.
[31] Khaw, Kay-Tee, et al. "Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk." Annals of Internal Medicine, vol. 141, 2004, pp. 413–420.
[32] Pradhan, Aruna D., et al. "Hemoglobin A1c predicts diabetes but not cardiovascular disease in nondiabetic women." American Journal of Medicine, vol. 120, 2007, pp. 110-117.
[33] Mann, Johannes F. E., et al. "Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial." Annals of Internal Medicine, vol. 134, 2001, pp. 629-636.